<DOC>
	<DOC>NCT01230710</DOC>
	<brief_summary>This open-label, single-arm study will evaluate the safety and efficacy of Tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer who have completed 4 cycles of standard platinum-based chemotherapy without progression. Patients will receive Tarceva at a dose of 150 mg orally daily until disease progression or unacceptable toxicity occurs.</brief_summary>
	<brief_title>A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patients â‰¥ 18 years of age. Histologically documented nonsmall cell lung cancer (NSCLC). Locally advanced or recurrent (Stage IIIB) or metastatic (Stage IV) disease. Completion of 4 cycles of an acceptable, standard, platinumbased chemotherapy doublet without progression. Eastern Cooperative Oncology Group (ECOG) performance status 01. Patients of reproductive potential must agree to use effective contraception. Prior exposure to agents directed at the human epidermal growth factor receptor (HER) axis (eg, gefitinib, cetuximab, trastuzumab). Prior treatment with any monoclonal antibody therapy. Any other malignancies within the previous 5 years, except for adequately treated carcinoma in situ of the cervix or squamous cell skin cancer. Clinically significant cardiovascular, hepatic, renal, or metabolic disease or active infection Preexisting interstitial lung disease. Human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Pregnant or lactating women.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>